OAM
ALDR

Oppenheimer Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Oppenheimer Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,260
Closed -$49K – 1732
2017
Q2 		$49K Sell
4,260
-123
-3% -$2.27K ﹤0.01% 1354
2017
Q1 		$91K Buy
+4,383
New +$97K ﹤0.01% 1211

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Oppenheimer Asset Management's ALDR Position: Q3 2017 in Review

Oppenheimer Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 4,260 shares — an estimated $49K sold.

Oppenheimer Asset Management first reported a position in ALDR in Q1 2017 and held it in 2 quarters. The position peaked at $91K in Q1 2017. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • Oppenheimer Asset Management reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 4,260 Alder Biopharmaceuticals shares in Q3 2017, an estimated $49K.
  • Oppenheimer Asset Management first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Oppenheimer Asset Management's Alder Biopharmaceuticals position peaked at $91K in Q1 2017.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Oppenheimer Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.